Jacobs Levy Equity Management
CSTL icon

Jacobs Levy Equity Management’s Castle Biosciences CSTL Stock Holding History

Jacobs Levy Equity Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-21,299
Closed -$426K – 1059
2025
Q1 		$426K Sell
21,299
-113,483
-84% -$2.81M ﹤0.01% 936
2024
Q4 		$3.59M Sell
134,782
-361,739
-73% -$11M 0.01% 485
2024
Q3 		$14.2M Sell
496,521
-21,456
-4% -$546K 0.05% 279
2024
Q2 		$11.3M Sell
517,977
-13,925
-3% -$310K 0.05% 316
2024
Q1 		$11.8M Sell
531,902
-4,885
-0.9% -$106K 0.05% 274
2023
Q4 		$11.6M Sell
536,787
-10,616
-2% -$187K 0.06% 287
2023
Q3 		$9.25M Buy
547,403
+289,252
+112% +$5.06M 0.05% 271
2023
Q2 		$3.54M Buy
+258,151
New +$5.23M 0.02% 470

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Jacobs Levy Equity Management's CSTL Position: Q2 2025 in Review

Jacobs Levy Equity Management sold out of Castle Biosciences (CSTL) in Q2 2025, closing a stake of 21,299 shares — an estimated $426K sold.

Jacobs Levy Equity Management first reported a position in CSTL in Q2 2023 and held it in 8 quarters. The position peaked at $14.2M in Q3 2024. 152 funds tracked by Wall St. Rank hold CSTL as of Q2 2025.

  • Jacobs Levy Equity Management reported no remaining Castle Biosciences position as of Q2 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 21,299 Castle Biosciences shares in Q2 2025, an estimated $426K.
  • Jacobs Levy Equity Management first reported a position in Castle Biosciences in Q2 2023 and held it in 8 quarters.
  • Jacobs Levy Equity Management's Castle Biosciences position peaked at $14.2M in Q3 2024.
  • 152 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2025, filed 14 Aug 2025.